Epigenetic inactivation of the MIR129-2 in hematological malignancies

Journal of Hematology & Oncology

Chor-Sang Chim¹  Dong-Yan Jin²  Raymond Liang¹  Florence Cheung⁵  Pak-Kwan Hui⁴  Chung-Ying Leung³  Yok-Lam Kwong¹  Rita Lok-Hay Yim¹  Kwan-Yeung Wong¹ 

[1] Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong;Department of Biochemistry, The University of Hong Kong, Hong Kong, Hong Kong;Department of Pathology, United Christian Hospital, Kowloon, Hong Kong;Department of Pathology, Kwong Wah Hospital, Kowloon, Hong Kong;Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong

关键词: Hematological cancers;    MIR129;    Hypermethylation;    Tumor suppressor;    microRNA;   

Others  :  812587
DOI  :  10.1186/1756-8722-6-16

 received in 2012-11-13, accepted in 2013-02-08,  发布年份 2013

【 摘 要 】

Background

MIR129-2 has been shown to be a tumor suppressor microRNA hypermethylated in epithelial cancers.

Patients and methods

Epigenetic inactivation of MIR129-2 was studied by methylation-specific PCR (MSP) in 13 cell lines (eight myeloma and five lymphoma), 15 normal controls and 344 primary samples including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM) at diagnosis, MM at relapse/progression, and monoclonal gammopathy of undetermined significance (MGUS). Expression of MIR129 and its target, SOX4, in cell lines was measured before and after hypomethylating treatment and MIR129 overexpression. MIR129 expression was correlated with MIR129-2 methylation status in primary lymphoma samples. Tumor suppressor function of MIR129 was demonstrated by MTT and trypan blue exclusion assay after MIR129 overexpression.

Results

The sensitivity of the methylated-MSP was one in 10³. Different MSP statuses, including complete methylation, partial methylation, and complete unmethylation, were verified by quantitative bisulfite pyrosequencing. All five lymphoma and seven of eight myeloma cell lines showed complete and partial MIR129-2 methylation. In primary samples, MIR129-2 methylation was absent in AML and CML, but detected in 5% ALL, 45.9% CLL, 49.5% MM at diagnosis, and 59.1% NHL. In CLL, MIR129-2 methylation adversely impacted on survival (p=0.004). In MM, MIR129-2 methylation increased from 27.5% MGUS to 49.5% MM at diagnosis and 41.5% at relapse/progression (p=0.023). In NHL, MIR129-2 methylation was associated with MIR124-1 and MIR203 methylation (p<0.001), and lower MIR129 expression (p=0.009). Hypomethylation treatment of JEKO-1, homozygously methylated for MIR129-2, led to MIR129-2 demethylation and MIR129 re-expression, with downregulation of SOX4 mRNA. Moreover, MIR129 overexpression in both mantle cell lines, JEKO-1 and GRANTA-519, inhibited cellular proliferation and enhanced cell death, with concomitant SOX4 mRNA downregulation.

Conclusions

MIR129-2 is a tumor suppressive microRNA frequently methylated in lymphoid but not myeloid malignancies, leading to reversible MIR129-2 silencing. In CLL, MIR129-2 methylation was associated with an inferior survival. In MM, MIR129-2 methylation might be acquired during progression from MGUS to symptomatic MM. In NHL, MIR129-2 methylation might collaborate with MIR124-1 and MIR203 methylation in lymphomagenesis.

【 授权许可】

   
2013 Wong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Chim CS, Liang R, Kwong YL: Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002, 20:167-176.
• [2]Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
• [3]Chim CS, Kwong YL, Liang R: Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin Lymphoma Myeloma 2008, 8:331-339.
• [4]Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
• [5]Chen C-Z: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005, 353:1768-1771.
• [6]Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
• [7]Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA: Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res Fundam Mol Mech Mutagen 2011, 717:77-84.
• [8]Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009, 125:2737-2743.
• [9]Huang Y-W, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang THM: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009, 69:9038-9046.
• [10]Shen R, Pan S, Qi S, Lin X, Cheng S: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun 2010, 394:1047-1052.
• [11]Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009, 69:4851.
• [12]Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, Perdomo C, Kotton D, Vaziri C, Anderlind C, et al.: miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 2010, 9:1809-1818.
• [13]Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, San Jose-Eneriz E, Abizanda G, Rodriguez-Otero P, Fortes P, et al.: Epigenetic silencing of the tumor suppressor MicroRNA Hsa-miR-124a Regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009, 69:4443-4453.
• [14]Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L: Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med 2011, 15:2760-2767.
• [15]Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF, Liang R: Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31:745-750.
• [16]Wong KY, So CC, Loong F, Chung LP, Lam WWL, Liang R, Li GKH, Jin D-Y, Chim CS: Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011, 6:e19027.
• [17]Wong KY, Yim RLH, So CC, Jin D-Y, Liang R, Chim CS: Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011, 118:5901-5904.
• [18]Lujambio A, Esteller M: CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007, 6:1455-1459.
• [19]Tsai K-W, Wu C-W, Hu L-Y, Li S-C, Liao Y-L, Lai C-H, Kao H-W, Fang W-L, Huang K-H, Chan W-C, Lin W-C: Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 2011, 129:2600-2610.
• [20]Penzo-Méndez AI: Critical roles for SoxC transcription factors in development and cancer. Int J Biochem Cell Biol 2010, 42:425-428.
• [21]Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. 2nd edition. Braunschweig: DSMZ – German Collection of Microorganisms and Cell Cultures; 2010.
• [22]Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz O, Oscier D: ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005, 90:1078-1088.
• [23]Chim CS, Fung T, Wong K, Lau J, Law M, Liang R: Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J Clin Pathol 2006, 59:921.
• [24]Chim CS, Fung TK, Wong KF, Lau JS, Liang R: Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J Hum Genet 2006, 51:832-838.
• [25]Chim CS, Pang R, Liang R: Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J Clin Pathol 2008, 61:1214-1219.
• [26]Liu T-H, Raval A, Chen S-S, Matkovic JJ, Byrd JC, Plass C: CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006, 66:653-658.
• [27]Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al.: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
• [28]Borkhardt A, Fuchs U, Tuschl T: MicroRNA in chronic lymphocytic leukemia. N Engl J Med 2006, 354:524-525. author reply 524–525
• [29]Chng WJ: MicroRNA in chronic lymphocytic leukemia. N Engl J Med 2006, 354:524-525. author reply 524–525
• [30]Bennett JM, Catovsky D, Marie-Theregse D, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias French-American-British (FAB) Co-operative Group. Br J Haematol 1976, 33:451-458.
• [31]Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
• [32]Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: International Agency for Research on Cancer; 2008.
• [33]Van den Berghe H: Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Br J Haematol 1988, 68:487-494.
• [34]International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757.
• [35]Blade JSD, Reece D, et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998, 102:1115-1123.
• [36]Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al.: Real-time quantification of microRNAs by stem–loop RT–PCR. Nucleic Acids Res 2005, 33:e179.
• [37]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 2001, 25:402-408.